

PATENT
Serial No. 08/372,676
Docket No. 304142800300
Docket No. 434-047

the application and the finality of the Office Action in view of the following Amendments and Remarks is respectfully requested.

AMENDMENTS

Please amend the claims as follows:

Please cancel all currently pending claims in the application without prejudice (Claims 1 and 4-26).

Please add the following new claims:

1 27. (New) An antibody having all the identifying characteristics of monoclonal antibody 1A7 produced by the hybridoma deposited under ATCC Accession No. HB-11786.

2 28. (New) Hybridoma designated 1A7 having ATCC Accession No. HB-11786, or progeny thereof producing a monoclonal antibody having all the identifying characteristics of the antibody produced by said hybridoma 1A7.

3 29. (New) Monoclonal antibody produced by the hybridoma or the progeny thereof according to claim 28.2

4 30. (New) Monoclonal antibody purified from the hybridoma or the progeny thereof according to claim 28.2

5 31. (New) A purified antibody having all the identifying characteristics of an antibody produced by the hybridoma according to claim 28.2

PATENT
Serial No. 08/372,676
Docket No. 304142800300
Docket No. 434-047

6 32. (New) An antibody according to claim 21 wherein said antibody further comprises a detectable label.

7 33. (New) An antibody according to claim 32, wherein said detectable label is selected from the group consisting of radiolabels, fluorescent labels and chemiluminescent labels.

8 34. (New) A diagnostic test kit for detecting an anti-GD2 antibody in a biological sample, comprising an antibody according to claim 21 in a suitable container.

9 35. (New) The diagnostic kit of claim 34, wherein the antibody is capable of binding anti-GD2.

10 36. (New) The diagnostic kit of claim 34, wherein the antibody is labeled with a detectable label.

11 37. (New) The diagnostic kit of claim 34, wherein the detectable label is selected from the group consisting of radiolabels, fluorescent labels, and chemiluminescent labels.

12 38. (New) The diagnostic kit of claim 34, also comprising an anti-immunoglobulin reagent labeled with a detectable label.

13 39. (New) The diagnostic kit of claim 34, wherein the biological sample is obtained from an individual suspected of having a GD2 antigen associated cancer.

26
3